News

NanoTemper and PharmAI: together faster to new drugs

NanoTemper and PharmAI: together faster to new drugs

NanoTemper Technologies and PharmAI collaborate to find suitable drug candidates by screening huge amounts of data.

Finding new drugs faster and easier: That's the goal of the collaboration between Dresden-based start-up PharmAI and Munich-based NanoTemper Technologies. The two partners want to contribute their respective expertise to the collaboration and enable even small laboratories to enter the field of drug discovery. This would, for example, enable more research into drugs for rare diseases, the development of which is currently rather unprofitable for large pharmaceutical companies.

NanoTemper Technologies develops devices and software solutions for the analysis of biomolecules. To this end, the Munich-based company combines various optical measurement methods that allow important statements to be made about molecules in terms of size, composition, durability or potential use as active ingredients. PharmAI, in turn, uses the company's own DiscoveryEngine software to track down suitable drug candidates with the help of artificial intelligence in large databases based on protein structure data. "We now want to bundle these competencies to create added value for our customers," explains Dr. Philipp Baaske, one of the two managing directors of NanoTemper Technologies.

Dr. Joachim Haupt, CEO of PharmAI sees virtual screening as the future: "Our software makes helpful predictions about drug candidates and reduces millions of possibilities to a manageable size," he explains. NanoTemper's equipment and software, he says, are capable of subsequently validating these predictions, allowing customers to proceed directly with the results.

In the coming months, the two companies plan to combine their technologies and develop a new generation of tools.

"Bringing life-saving drugs and therapies to market is more important than ever. To make big leaps in research quickly, the focus for these new drug discovery tools is reliability and ease of use, so they can be used by as many people as possible," says Philipp Baaske.

NanoTemper was founded in 2008 and now has over 170 employees and is represented in 13 countries worldwide. PharmAI was founded in 2019 as a spin-off of the Technical University of Dresden.


Newsletter

Subscribe

Archive